BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed QNRX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:e60954abfbb724172f7b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:QNRX P2/P3 readout (est.): Open Label\, Safety and Efficacy Study o
 f QRX003 Lotion in Subjects With Netherton Syndrome
DESCRIPTION:Open Label\, Safety and Efficacy Study of QRX003 Lotion in Subj
 ects With Netherton Syndrome\nNCT05789056 | PHASE2/PHASE3 | RECRUITING | s
 ponsor: Quoin Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nTicker QNRX (confidence 0.9)\nSource: h
 ttps://clinicaltrials.gov/study/NCT05789056\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05789056
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ee17d9746811a2deec89@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:QNRX P2/P3 readout (est.): Clinical Study of QRX003 Lotion in Subje
 cts With Netherton Syndrome
DESCRIPTION:Clinical Study of QRX003 Lotion in Subjects With Netherton Synd
 rome\nNCT06953466 | PHASE2/PHASE3 | RECRUITING | sponsor: Quoin Pharmaceut
 icals\nPrimary completion date (ESTIMATED)\; top-line results usually foll
 ow later.\nTicker QNRX (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT06953466\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06953466
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7cb8baf4d94811d73085@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:QNRX P2/P3 readout (est.): Phase 2/3 Clinical Study of QRX003 Lotio
 n in Subjects With Netherton Syndrome
DESCRIPTION:Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Neth
 erton Syndrome\nNCT07538583 | PHASE2/PHASE3 | RECRUITING | sponsor: Quoin 
 Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-line results us
 ually follow later.\nTicker QNRX (confidence 0.9)\nSource: https://clinica
 ltrials.gov/study/NCT07538583\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07538583
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
